Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Zachary L. Taylor"'
Autor:
Zachary L. Taylor, Ethan A. Poweleit, Kelli Paice, Katherine M. Somers, Kathryn Pavia, Alexander A. Vinks, Nieko Punt, Tomoyuki Mizuno, Sonya Tang Girdwood
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 12, Pp 1827-1845 (2023)
Abstract There has been rising interest in using model‐informed precision dosing to provide personalized medicine to patients at the bedside. This methodology utilizes population pharmacokinetic models, measured drug concentrations from individual
Externí odkaz:
https://doaj.org/article/56d8ea879ac64219a5762377a87769e5
Autor:
Zachary L. Taylor, Tamara P. Miller, Ethan A. Poweleit, Nicholas P. DeGroote, Lauren Pommert, Oluwafunbi Awoniyi, Sarah G. Board, Ngozi Ugboh, Vivek Joshi, Nick Ambrosino, Ashley Chavana, Melanie B. Bernhardt, Eric S. Schafer, Maureen M. O'Brien, Sharon M. Castellino, Laura B. Ramsey
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 11, Pp 2130-2143 (2023)
Abstract The MTXPK.org webtool was launched in December 2019 and was developed to facilitate model‐informed supportive care and optimal use of glucarpidase following the administration of high‐dose methotrexate (HDMTX). One limitation identified
Externí odkaz:
https://doaj.org/article/5f03661676c74213b95f1b9c76080e52
Autor:
Jeffrey R. Strawn, Ethan A. Poweleit, Zachary L. Taylor, Tomoyuki Mizuno, Samuel Vaughn, Zeruesenay Desta, Stephani Stancil, Laura B. Ramsey
Publikováno v:
Journal of Clinical and Translational Science, Vol 8, Pp 22-23 (2024)
OBJECTIVES/GOALS: Developing pharmacokinetic (PK) models to guide selective serotonin reuptake inhibitor (SSRI) dosing in youth is costly, time-intensive, and requires large numbers of participants. We evaluated the use of remnant blood samples from
Externí odkaz:
https://doaj.org/article/e1d8503c9362423ea58b12fa2f44074f
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 1, Pp 63-69 (2022)
Abstract Low‐dose methotrexate (MTX) is an immunosuppressant used to treat inflammatory bowel disease (IBD). SLCO1B1 genetic variation has been associated with delayed MTX clearance and increased toxicity. The purpose of this study was to evaluate
Externí odkaz:
https://doaj.org/article/7312e4e443344c46acccaabfd37284d5
Autor:
Zachary L. Taylor, Lauren E. Thompson, Heather Bear, Tomoyuki Mizuno, Alexander A. Vinks, Laura B. Ramsey
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2267-2277 (2021)
Abstract Low‐dose methotrexate (MTX) is a first‐line therapy for the treatment of arthritis. However, there is considerable interindividual variability in MTX exposure following standard dosing. Polymorphisms in SLCO1B1 significantly effect MTX c
Externí odkaz:
https://doaj.org/article/a6b2dde967344193adb79c03c44199eb
Autor:
Zachary L. Taylor, Jesper Vang, Elixabet Lopez-Lopez, Natanja Oosterom, Torben Mikkelsen, Laura B. Ramsey
Publikováno v:
Cancers, Vol 13, Iss 11, p 2837 (2021)
Methotrexate (MTX) is a mainstay therapeutic agent administered at high doses for the treatment of pediatric and adult malignancies, such as acute lymphoblastic leukemia, osteosarcoma, and lymphoma. Despite the vast evidence for clinical efficacy, hi
Externí odkaz:
https://doaj.org/article/59db8fb3ce954fa282fbbdd105bd1658
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 19:1-11
Autor:
Manuel Ibarra, Ryan Combs, Zachary L. Taylor, Laura B. Ramsey, Torben Mikkelsen, Randal K. Buddington, Jesper Heldrup, Jason N. Barreto, Martin Guscott, Jennifer Lowe, Charles Hurmiz, Suresh Marada, Scott C. Howard, Paula Schaiquevich
Publikováno v:
Ibarra, M, Combs, R, Taylor, Z L, Ramsey, L B, Mikkelsen, T, Buddington, R K, Heldrup, J, Barreto, J N, Guscott, M, Lowe, J, Hurmiz, C, Marada, S, Howard, S C & Schaiquevich, P 2023, ' Insights from a pharmacometric analysis of HDMTX in adults with cancer : Clinically relevant covariates for application in precision dosing ', British Journal of Clinical Pharmacology, vol. 89, no. 2, pp. 660-671 . https://doi.org/10.1111/bcp.15506
AIMS: High-dose methotrexate (HDMTX) is an essential part of the treatment of several adult and paediatric malignancies. Despite meticulous supportive care during HDMTX administration, severe toxicities, including acute kidney injury (AKI), may occur
Autor:
Helena K. Kim, Xiaoyu Men, Daniel M. Blumberger, Jordan F. Karp, Eric Lenze, Daniel J. Müller, Laura B. Ramsey, Charles F. Reynolds, Zachary L. Taylor, Benoit H. Mulsant
Publikováno v:
The American Journal of Geriatric Psychiatry. 31:S102-S103
Autor:
Laura B. Ramsey, Lauren E. Thompson, Zachary L. Taylor, Tomoyuki Mizuno, Alexander A. Vinks, Heather Bear
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2267-2277 (2021)
Clinical and Translational Science
Clinical and Translational Science
Low‐dose methotrexate (MTX) is a first‐line therapy for the treatment of arthritis. However, there is considerable interindividual variability in MTX exposure following standard dosing. Polymorphisms in SLCO1B1 significantly effect MTX clearance,